This is an aggregated industry headline. Read the full story at KFF Health News →
Abortion Pill’s Safety Called into Question in Congressional Actions Based on Misleading Data — The Monitor
False claims about the safety of mifepristone are driving legislative and investigative action in Congress, even as major medical organizations and decades of clinical evidence support the drug’s safety. And competing interpretations of what censorship and free speech mean are impacting how health m
By KFF Health News
· Apr 9, 2026
· via KFF Health News
Image: KFF Health News
Tags
policyformat:headlineheadlineKFF Health News
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Policy
All Policy →
PolicyFierceBiotech ↗
As an outbreak of Ebola in central Africa continues to worsen, the federal government has tapped a little-know…
PolicyBriefing
Eli Lilly’s lawsuit claims church-affiliated pharmacies and wholesalers defrauded it through fake rebate claim…
PolicySTAT News ↗
The Trump administration disclosed plans to reduce state directed payments even more, setting up a probable sh…